Biogen Inc. (ETR:IDP)
Germany · Delayed Price · Currency is EUR | Market Cap | 18.49B |
| Revenue (ttm) | 8.51B |
| Net Income (ttm) | 1.30B |
| Shares Out | n/a |
| EPS (ttm) | 8.90 |
| PE Ratio | 14.19 |
| Forward PE | 9.58 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 994 |
| Average Volume | 587 |
| Open | 128.75 |
| Previous Close | 129.55 |
| Day's Range | 126.10 - 130.10 |
| 52-Week Range | 99.00 - 177.50 |
| Beta | 0.13 |
| RSI | 53.73 |
| Earnings Date | Oct 30, 2025 |
About Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r... [Read more]
Financial Performance
In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.
Financial numbers in USD Financial StatementsNews
Biogen (BIIB) Sees Decline After Launching New Alzheimer's Drug Formulation
Biogen (BIIB) Sees Decline After Launching New Alzheimer's Drug Formulation
Biogen (BIIB) and Eisai Launch New Form of Alzheimer's Drug
Biogen (BIIB) and Eisai Launch New Form of Alzheimer's Drug
Eisai And Biogen : LEQEMBI IQLIK Injection Now Available In U.S. For Early Alzheimer's Treatment
(RTTNews) - Eisai Co., Ltd. (ESALY.PK, ESALF.PK, 4523.T) and Biogen Inc. (BIIB) announced the U.S. availability of LEQEMBI IQLIK (lecanemab-irmb) as a subcutaneous injection for maintenance dosing in ...
Biogen (BIIB) Launches New Alzheimer's Treatment in the U.S.
Biogen (BIIB) Launches New Alzheimer's Treatment in the U.S.
Biogen (BIIB) Launches New Alzheimer's Treatment Option in U.S.
Biogen (BIIB) Launches New Alzheimer's Treatment Option in U.S.
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
New LEQEMBI Companion ™ program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an i...
Eisai and Biogen Announce U.S. Availability of LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease
New LEQEMBI Companion program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an inj...
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
New LEQEMBI CompanionTM program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an i...
Monday Sector Laggards: Healthcare, Consumer Products
The worst performing sector as of midday Monday is the Healthcare sector, showing a 0.6% loss. Within that group, Biogen Inc (Symbol: BIIB) and Baxter International Inc (Symbol: BAX) are two of the da...
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
BIIB Stock: Is Biogen Still A Buy After The 14% Spike?
Biogen (BIIB) shares recorded their fifth consecutive day of increases, accumulating a total return of 14% during this span. The company's market value has increased by approximately $3.3 billion over...
Chart Master: A breakout could signal more upside for beaten-down pharma stocks
Carter Worth, Worth Charting, joins Fast Money with the technicals on the pharma sector, bullish reversal patterns in Merck, Biogen, and Pfizer, why bombed-out names may offer more upside than Johnson...
‘Fast Money' traders talk opportunities in health care stocks
The Fast Money traders discuss why health care stocks look attractive on valuations, how underweight positioning could drive sustainability, why recent White House policy moves may be a “gift” to phar...
Noteworthy Wednesday Option Activity: BIIB, OXY, BSX
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Biogen Inc (Symbol: BIIB), where a total of 7,540 contracts have traded so far, representin...
Wednesday Sector Leaders: Healthcare, Utilities
Looking at the sectors faring best as of midday Wednesday, shares of Healthcare companies are outperforming other sectors, up 1.6%. Within the sector, Eli Lilly (Symbol: LLY) and Biogen Inc (Symbol: B...
Amgen and Biogen settle patent dispute over Prolia and Xgeva biosimilars
Eisai : LEQEMBI Approved In China For Monthly IV Maintenance Dosing In Early Alzheimer's Treatment
(RTTNews) - Eisai Co., Ltd. (ESALY.PK, ESALF.PK, 4523.T) and Biogen Inc. (BIIB) announced that the National Medical Products Administration (NMPA) of China has approved LEQEMBI—a humanized monoclonal ...
Biogen (BIIB) Secures Approval for LEQEMBI's Monthly Dosing in China
Biogen (BIIB) Secures Approval for LEQEMBI's Monthly Dosing in China
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China
TOKYO and CAMBRIDGE, Mass., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massac...
Portal Innovations' John Flavin: Tariffs on pharma could raise costs and delay drug access
John Flavin, Portal Innovations founder and CEO, joins CNBC's 'Squawk on the Street' to discuss the Trump administration's proposed pharmaceutical tariffs, the impact on biotech startups and clinical ...
Biogen (BIIB) Shares Cross Below 200 DMA
In trading on Thursday, shares of Biogen Inc (Symbol: BIIB) crossed below their 200 day moving average of $135.70, changing hands as low as $135.66 per share. Biogen Inc shares are currently trading d...
Biogen Faces FDA Setback On High-Dose Nusinersen Filing For Spinal Muscular Atrophy
On Tuesday, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for Biogen Inc.’s (NASDAQ: BIIB) supplemental New Drug Application (sNDA) for the high-dose regimen of ...
This Biogen Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
Jefferies Initiates Coverage on Biogen (BIIB) with Buy Rating | BIIB Stock News
Jefferies Initiates Coverage on Biogen (BIIB) with Buy Rating | BIIB Stock News
Biogen Inc. (BIIB) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
Biogen Inc. (NASDAQ:BIIB) Bernstein 2nd Annual Global Healthcare Conference September 24, 2025 11:20 AM EDT Company Participants Priya Singhal - Executive VP & Head of Development Conference Call Par...